APAC local pharmaceutical firms challenge multinational dominance | Healthcare Asia Magazine
, APAC
Photo from Envato

APAC local pharmaceutical firms challenge multinational dominance

This development is attributed to increased R&D investments and supportive government policies.

The Asia Pacific’s (APAC) pharmaceutical landscape is undergoing a shift as local companies begin to challenge the dominance of multinational drugmakers, said BMI.

This development is attributed to increased investment in research and development (R&D), growing healthcare demands, and the rise of chronic diseases in the region.

Moreover, supportive government policies are driving the sector’s advancement.

One key example is India’s “Make in India” initiative in 2014, which aims to encourage both multinational and domestic firms to manufacture their products within the market.

“The initiative also offers tax benefits, subsidies and simplified regulatory procedures to attract investments in the pharmaceutical sector,” the report said.

Meanwhile, Mainland China has come up with the “Made in China 2025” plan to move the region up the value chain in several industries, including pharmaceuticals.

Improved regulatory frameworks in APAC markets are also boosting the competitiveness of local companies.

Efforts to harmonise standards through initiatives like the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the APEC Life Sciences Innovation Forum are streamlining the region’s drug approval processes.

In line with this, the Association of Southeast Asian Nations (ASEAN) has been particularly active in working towards a unified regulatory environment for pharmaceuticals.

However, local firms still face significant challenges as competing with multinational corporations with advanced R&D capabilities and extensive supply chains remains difficult. 

Additionally, adhering to international quality standards, such as those set by the International Council for Harmonisation (ICH), demands substantial investment in quality control, R&D, and infrastructure.

“This can be a costly and time-consuming endeavour, especially for smaller companies with limited financial resources,” the report added.

 

Follow the link for more news on

Pemindaian AI terkini meningkatkan diagnosa di Shin Kong Wu Ho-Su Memorial Hospital

Rumah sakit di Taiwan ini menggunakan teknologi endoskop yang dibantu AI untuk mendeteksi polip dan kamera resolusi tinggi untuk telemedis.

KFSHRC Saudi bertumpu pada inovasi untuk mentransformasi layanan kesehatan

Rumah sakit ini mempercepat adopsi teknologi baru untuk memposisikan dirinya sebagai pemimpin global di bidang kedokteran.

Angkor Hospital merencanakan pusat trauma untuk anak-anak

Fasilitas ini akan memiliki ICU, ruang gawat darurat, ruang operasi, dan bangsal bedah.

Bali International Hospital dan HK Asia Medical mendirikan pusat jantung baru

Fasilitas ini akan menawarkan diagnostik, operasi invasif minimal, dan perawatan pasca operasi.

Pasar pencitraan medis Indonesia diproyeksikan tumbuh 6,12% CAGR hingga 2030

Salah satu pendorong utama adalah peningkatan inisiatif yang dipimpin pemerintah.

Rumah Sakit Pusat Kamboja beralih ke adopsi teknologi untuk meningkatkan layanan jantung

Salah satu teknologi kunci mereka adalah mesin ECMO untuk mendukung hidup yang berkepanjangan dalam kondisi kritis.

Ekspor farmasi Indonesia diperkirakan tumbuh 7,7% CAGR hingga 2028

Berkat upaya pemerintah dan aturan investasi baru untuk meningkatkan produksi domestik.

Jepang dan Indonesia tandatangani MoU untuk pelatihan perawat dan pekerja perawatan

Kemitraan ini bertujuan membimbing tenaga kesehatan Indonesia agar memenuhi standar tenaga kerja profesional Jepang.

Pusat gigi nasional Singapura berada di garda terdepan layanan gigi digital

Teknologi pemindaian intraoralnya menggantikan metode pencetakan gigi tradisional.

Inovasi medis global dan solusi berbasis AI menjadi sorotan

Medical Taiwan 2024 menghadirkan 280 peserta dari 10 negara dan mendorong integrasi teknologi dalam layanan kesehatan.